Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Atea (AVIR) Plunges on Termination of Collaboration With Roche

by Zacks Equity Research

Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.

Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe

by Zacks Equity Research

Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.

AstraZeneca (AZN), Moderna's Heart Failure Study Successful

by Zacks Equity Research

AstraZeneca (AZN) and Moderna are developing an mRNA-based therapeutic to treat heart failure in patients undergoing coronary artery bypass surgery.

Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail

by Zacks Equity Research

Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.

Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm

by Zacks Equity Research

Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.

Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion

by Zacks Equity Research

Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.

AstraZeneca (AZN) Q3 Earnings Miss, Sales Beat, Stock Down

by Zacks Equity Research

AstraZeneca (AZN) surpasses third-quarter estimates for revenues while missing the same for earnings. The company retains 2021 guidance.

Epizyme (EPZM) Q3 Loss Wider Than Expected, Revenues Up

by Zacks Equity Research

Epizyme (EPZM) posts a wider-than-expected loss in the third quarter and revenues miss estimates. Nevertheless, the pipeline progress is encouraging.

Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Puma (PBYI) Misses on Q3 Earnings, Cuts Sales View, Stock Down

by Zacks Equity Research

Puma Biotech (PBYI) reports lower-than-expected Q3 earnings and sales. It slashes 2021 Nerlynx sales guidance.

Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus

by Zacks Equity Research

Prothena misses on earnings and revenues in the third quarter of 2021. Nevertheless, the company's progress with its AD pipeline is encouraging.

Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth

by Zacks Equity Research

Regeneron (REGN) beats on Q3 earnings while sales record strong year-over-year growth on the solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.

Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the third quarter. The company also raises revenues guidance for the year. Stock up in after-market trading.

Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Ionis (IONS) incurs wider-than-expected Q3 loss. The company maintains its top-and bottom-line guidance for 2021

Amgen (AMGN) Q3 Earnings Top, Sales View Tightened, Stock Down

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for both earnings and sales. It lowers the upper end of the sales guidance for 2021 while raising the earnings range.

Halozyme (HALO) Beats on Q3 Earnings, Tweaks 2021 Guidance

by Zacks Equity Research

Halozyme (HALO) third-quarter earnings and sales beat estimates. The company raises the lower end of its previously guided range for earnings and revenues for 2021. Stock up.

ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.

ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.

Seagen (SGEN) Q3 Loss Widens, Revenues Beat, 2021 Guidance Up

by Zacks Equity Research

Seagen's (SGEN) earnings miss estimates in the third quarter of 2021 while revenues beat the same. The company increases its financial guidance for 2021.

Blueprint Medicines (BPMC) Misses on Q3 Earnings & Revenues

by Zacks Equity Research

Blueprint Medicines (BPMC) misses earnings and revenue estimates for the third quarter of 2021. Yet, the stock price surges as the company provides encouraging pipeline updates.

AbbVie's (ABBV) Q3 Earnings Beat, 2021 EPS Guidance Raised

by Zacks Equity Research

AbbVie (ABBV) beats third-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares increased following the results.

Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings

by Zacks Equity Research

AbbVie (ABBV) is expected to have witnessed a recovery in demand trends of new drugs amid the receding impact of the pandemic. However, sales of physician-administered drugs are likely to have been hurt by the residual impact.

Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study

by Zacks Equity Research

Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

by Kinjel Shah

J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.

Regeneron (REGN) Dupixent Gets FDA Nod for Asthma in Children

by Zacks Equity Research

Regeneron (REGN) and Sanofi's (SNY) Dupixent secures FDA approval to treat children aged 6-11 years with moderate to severe asthma.